Treatment for Pruritus in Chronic Kidney Disease (CKD)

Introduction to CKD-Associated Pruritus

• The British Journal of Dermatology recommends a stepwise approach for managing CKD-associated pruritus, starting with optimization of dialysis adequacy, normalization of calcium-phosphate balance, control of parathyroid hormone levels, correction of anemia with erythropoietin, and use of emollients before implementing other treatment strategies 1, 2, 3

First-Line Treatments

• Emollients should be provided as supportive care to address xerosis (dry skin), which is the most common cutaneous sign in dialysis patients and may lower the threshold for itch 1, 3
• Ensure adequate dialysis - pruritus is more common in underdialysed patients and symptoms may improve by increasing dialysis dose (target Kt/V of around 1.6) 1, 3
• Normalize calcium-phosphate balance and control parathyroid hormone to accepted levels, as secondary and tertiary hyperparathyroidism often accompany ESRD and may contribute to pruritus 1, 3
• Correct anemia with erythropoietin if present 1, 3

Second-Line Treatments

• Topical capsaicin 0.025% cream applied four times daily has shown significant efficacy in randomized trials, with 14 out of 17 patients reporting marked relief and 5 achieving complete remission of pruritus 1, 2
• Broad-band UVB (BB-UVB) phototherapy is an effective treatment for many patients with uremic pruritus with strong evidence supporting its use 4

Third-Line Treatments

• Topical doxepin can be considered for severe cases, but treatment should be limited to 8 days, 10% of body surface area, and 12 g daily 5
• Non-sedative antihistamines such as fexofenadine 180 mg or loratadine 10 mg, or mildly sedative agents such as cetirizine 10 mg may be tried, though evidence for their efficacy specifically in uremic pruritus is limited 4, 5

Important Considerations and Pitfalls

• Long-term use of sedative antihistamines may predispose to dementia and should be avoided except in palliative care settings 2, 4
• Cetirizine is not effective specifically for uremic pruritus despite its use in other pruritic conditions 4
• Renal transplantation is the only definitive treatment for uremic pruritus but is not always feasible 4

Monitoring and Follow-up

• Pruritus in CKD patients can be generalized (in approximately 50% of cases) or localized (commonly affecting the back, face, or arteriovenous fistula arm) 1
• The intensity can range from mild intermittent irritation to intractable itch that severely disrupts sleep and quality of life 1, 3
• Pruritus may worsen during summer or at night, and some patients experience itch during or soon after dialysis treatment 1, 3

Management of Chronic Uremic Pruritus in Hemodialysis Patients

First-Line Approach: Optimize Dialysis Parameters

• The British Journal of Dermatology recommends ensuring adequate dialysis, with a target Kt/V of around 1.6, as pruritus is more common in underdialysed patients 6
• Normalized calcium-phosphate balance and controlled parathyroid hormone levels are essential, according to the British Journal of Dermatology 6
• Regular use of emollients to address xerosis (dry skin) is crucial, as it is the most common cutaneous manifestation in dialysis patients, as reported by the British Journal of Dermatology 6

Pharmacologic Treatment Algorithm

First-Line Medication

• Gabapentin 100-300 mg after each dialysis session (three times weekly) is the most effective medication for treating chronic pruritus due to uremia in hemodialysis patients, with a good response rate and a significant reduction in visual analogue ratings, as shown in a multicentre, double-blind, placebo-controlled trial, according to the British Journal of Dermatology 7, 6, 8
• The British Journal of Dermatology notes that these doses are lower than those used in non-ESRD populations due to reduced renal clearance 6
• Common side effects of gabapentin include mild drowsiness, as reported by the British Journal of Dermatology 7

Alternative/Adjunctive Treatments

• Topical capsaicin cream (0.025%) applied to affected areas can be effective, as it acts by depleting neuropeptides including substance P in peripheral sensory neurons, according to the British Journal of Dermatology 7, 6
• Topical calcipotriol can be used for localized areas, as recommended by the British Journal of Dermatology 7, 8
• Doxepin (10 mg twice daily) can be used for short-term treatment, with complete resolution reported in 58% of patients vs. 8% on placebo, but caution is advised due to potential drowsiness, as reported by the British Journal of Dermatology 6, 8

Important Considerations and Pitfalls

• The British Journal of Dermatology advises avoiding cetirizine (10 mg daily) as it has been shown ineffective specifically for uremic pruritus 7, 8
• Long-term sedative antihistamines should be avoided except in palliative situations, as they may predispose to dementia, according to the British Journal of Dermatology 7, 6
• Ketotifen (1 mg daily) may be as effective as gabapentin, but has less supporting evidence overall, as reported by the British Journal of Dermatology 7, 6
• Renal transplantation remains the only definitive treatment for uremic pruritus, but is not always feasible, according to the British Journal of Dermatology 8

Topical Treatments for Uremic Pruritus

First-Line Topical Approach

• The British Journal of Dermatology recommends using capsaicin 0.025% cream applied to affected areas four times daily for uremic pruritus, with strong evidence supporting its efficacy 9

Topical Agents to AVOID

• The British Journal of Dermatology advises against using calamine lotion for uremic pruritus, as there is no literature supporting its use 9
• The British Journal of Dermatology also recommends avoiding crotamiton cream, as it has been shown to be not effective compared to vehicle control 9

Second-Line Topical Options

• The British Journal of Dermatology suggests that topical doxepin may be considered for severe cases of uremic pruritus, but treatment must be strictly limited to 8 days, 10% of body surface area, and maximum 12 g daily 9

Treatment Escalation

• If topical treatments provide insufficient relief after 2-4 weeks of consistent use, the British Journal of Dermatology recommends escalating to systemic therapy with gabapentin or considering BB-UVB phototherapy 10

Efficacy and Mechanism of Topical Capsaicin for Uremic Pruritus

Clinical Efficacy

• In a small randomized trial of patients with end‑stage renal disease–associated pruritus, five individuals achieved complete remission after using 0.025 % capsaicin cream, and the antipruritic benefit persisted for up to eight weeks after discontinuation of therapy【11】. (Evidence level: low‑quality trial)

Mechanism of Action

• The antipruritic effect of topical capsaicin is attributed to depletion of the neuropeptide substance P in peripheral sensory neurons, reducing itch signaling【11】. (Evidence level: mechanistic observation from the same trial)

Recommendations on Topical Therapies for Uremic Pruritus in End‑Stage Renal Disease

Menthol – Not Recommended

• The British Association of Dermatologists advises that menthol should not be used for uremic pruritus because it provides only a counter‑irritant effect and lacks a true antipruritic mechanism. 12
• The same guideline specifies that topical capsaicin is an exception to the general recommendation against using it for generalized pruritus of unknown origin, but this exception does not extend to menthol. 12

Combination of Capsaicin with Menthol – Not Supported

• Evidence from a Mayo Clinic Proceedings article indicates that the combination of capsaicin and menthol has only been described for erythromelalgia, a condition unrelated to uremic pruritus, and there is no supporting data for its use in ESRD‑associated itch. 13

Other Topical Agents to Avoid

• The British Association of Dermatologists states that calamine lotion has no supporting literature for efficacy in uremic pruritus and should be avoided. 12
• The same guideline reports that crotamiton cream was shown to be ineffective compared with vehicle control in this patient population. 12

Patient Counseling on Capsaicin Use (Supported by Mayo Clinic Proceedings)

• Patients should be informed that an initial burning or stinging sensation may occur when starting capsaicin 0.025 % cream, but these sensations typically resolve with continued application. 13

Topical Capsaicin for Perianal Pruritus in Hemodialysis Patients

Efficacy

Duration of Effect

Management of Chronic Pruritus in Hemodialysis Patients

Assessment and Optimization of Dialysis Parameters

• Ensure adequate dialysis adequacy with a target Kt/V of approximately 1.6, as insufficient dialysis is associated with a higher prevalence of pruritus. 15
• Maintain balanced calcium‑phosphate levels and keep parathyroid hormone within acceptable ranges to help control itch symptoms. 15
• Apply moisturizers regularly to treat xerosis, the most common cutaneous manifestation in patients receiving hemodialysis. 15

First‑Line Systemic Pharmacotherapy

• Gabapentin administered intravenously after each dialysis session (3 times/week) at an initial dose of 100 mg, titratable to 200 mg if response is inadequate, with a maximum of 300 mg per dose. This lower dosing reflects reduced renal clearance compared with non‑renal patients. 15
• High‑quality evidence (multicenter, double‑blind, placebo‑controlled trial) shows that gabapentin reduces visual analogue scale (VAS) itch scores by > 50 % compared with placebo, with a good overall response rate. 15
• The most common adverse effect of gabapentin in this setting is mild drowsiness. 15

Adjunctive Topical Therapies

• Capsaicin cream 0.025 % applied four times daily to affected areas leads to marked improvement in the majority of patients (14 / 17 improved, 5 achieved complete resolution). 15
• Calcipotriol can be used topically for localized pruritic patches when needed. 15

Antihistamine Use – What to Avoid

• Cetirizine does not provide effective relief for uremic pruritus, despite its efficacy in other itch conditions. 15
• Long‑term use of sedating antihistamines such as diphenhydramine or hydroxyzine should be avoided because they may increase the risk of cognitive decline. 15

Definitive Curative Option

• Kidney transplantation remains the only definitive cure for uremic pruritus, although it may not be feasible for all patients. 15

Pharmacologic Management of CKD‑Associated Pruritus in Hemodialysis Patients

Optimizing Dialysis Parameters

• Achieving an adequate dialysis dose (target Kt/V ≈ 1.6) reduces the prevalence of pruritus in under‑dialyzed patients. Evidence: observational data showing higher itch rates with lower Kt/V. 16

• Normalizing calcium‑phosphate balance and parathyroid hormone levels, and correcting anemia with erythropoietin, are recommended adjuncts because secondary/tertiary hyperparathyroidism and anemia can exacerbate itch. Evidence: expert consensus linking these metabolic disturbances to pruritus. 16

• Regular use of emollients to treat xerosis (dry skin) lowers the skin‑sensitivity threshold and helps control itch. Evidence: clinical observation in dialysis cohorts. 16

First‑Line Systemic Pharmacotherapy

• Gabapentin administered intravenously after each dialysis session (100 mg, titrated to 200 mg if needed, max 300 mg) is the first‑line drug for CKD‑associated pruritus. Strength of evidence: multicenter, double‑blind, placebo‑controlled trial showing > 50 % reduction in visual analogue itch scores with good overall response rates. 17

• The low dosing regimen reflects reduced renal clearance in dialysis patients, contrasting with higher doses used in non‑ESRD populations. Evidence: pharmacokinetic considerations described in the same trial. 17

Topical Adjunctive Therapies

• Capsaicin 0.025 % cream applied four times daily to affected areas improves itch in the majority of patients (14/17 improved; 5 achieved complete remission). Strength of evidence: small prospective study indicating marked benefit. 16

• Capsaicin’s mechanism involves depletion of peripheral neuropeptides (e.g., substance P), providing antipruritic effect that can persist up to 8 weeks after discontinuation. Evidence: mechanistic explanation from trial data. 17

• Calcipotriol cream may be used for localized pruritic patches when capsaicin is unsuitable. Evidence: reported use in the same clinical series. 17

Non‑Pharmacologic Therapy

• Broad‑band UVB phototherapy is an effective option for patients who do not respond to or cannot tolerate medications. Strength of evidence: supportive data from dialysis cohort studies demonstrating significant itch reduction. 16

Emerging and FDA‑Approved Therapy

• Difelikefalin, a kappa‑opioid receptor agonist, is the only FDA‑approved medication specifically for CKD‑associated pruritus in the United States and Europe. Large‑scale trials involving > 1,400 hemodialysis patients treated for up to 64 weeks showed significant and sustained itch relief. Strength of evidence: high‑quality randomized controlled trials. 16

Medications to Avoid

• Cetirizine lacks efficacy for uremic pruritus and should not be used. Evidence: negative findings in comparative studies. 17

• Long‑term sedating antihistamines (e.g., diphenhydramine, hydroxyzine) are discouraged except in palliative settings due to risk of cognitive decline. Evidence: safety concerns highlighted in clinical reviews. 17

• Calamine lotion, crotamiton cream, and menthol have no proven antipruritic benefit for CKD‑related itch and are not recommended. Evidence: absence of supportive literature. 17

Clinical Pitfalls and Dosing Considerations

• Standard non‑renal gabapentin dosing regimens are inappropriate for dialysis patients; the recommended reduced dose (100–300 mg post‑dialysis) prevents excess sedation and accumulation. Evidence: dosing error warnings from trial protocols. 17

• When using topical doxepin for severe cases, limit application to ≤ 10 % body surface area, ≤ 12 g per day, and a maximum of 8 days to avoid systemic toxicity. Evidence: safety limits described in renal‑specific guidelines. 16

Definitive Treatment

• Renal transplantation offers the only definitive cure for uremic pruritus and should be considered for eligible patients with refractory severe itch. Evidence: observational data linking transplantation to resolution of pruritus. 17

Impact on Quality of Life

• CKD‑associated pruritus is linked to poorer health‑related quality of life, disrupted sleep, depression, higher hospitalization rates, and increased mortality, underscoring the need for aggressive management. Evidence: cohort analyses demonstrating these associations. 16